{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 49,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "propose_solution",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a Venn-style diagram to illustrate market expansion.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/35",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Planning to initiate Phase III trial in 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67a4d56a-9c04-49ee-8af7-88bff04f2538",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.4,
        "x": 0.55,
        "y": 0.24
      },
      "kind": "chart",
      "text": "Venn diagram showing Strensiq population inside larger ALXN1850 population",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1836ee2-5e1b-4776-945e-02a513cd4c18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.22,
        "x": 0.03,
        "y": 0.27
      },
      "kind": "image",
      "text": "Molecular structure of ALXN1850",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18405ca7-0a68-4b53-a096-2a6f06be6b52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.24,
        "y": 0.37
      },
      "kind": "list",
      "text": "Longer half-life, less frequent QW SC dosing; Improved PK; Increased enzymatic activity; Higher bioavailability; Higher in-vivo exposure; Improved manufacturing process",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d464b4e5-d598-4dc3-99a5-884bc3eeba9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Increase in addressable population driven by expanded indication of ALXN1850 to include patients with adult-onset HPP (vs perinatal/infantile and juvenile onset only with Strensiq (ex-JP)) HPP = hypophosphatasia; QW = once-weekly; SC = subcutaneous; PK = pharmacokinetics.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56b0a228-a794-4308-a3f0-0a451c423703",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.95,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Patient-centered innovation, optimised molecule to extend half-life, less frequent dosing",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c918f844-5ad5-4c6c-a09a-d0cadfc03598",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "ALXN1850: next-generation HPP",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77f6421c-831b-4e79-82e5-5fb5ece306be",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Venn diagram",
      "slug": "venn-diagram",
      "agent": null,
      "layer": "slide",
      "matchId": "f64a2521-4e8b-4e1e-b428-d2714f2c67fd",
      "evidence": "chart/pie: Venn diagram showing Strensiq population inside larger ALXN1850 population",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "434a6c7a-b0ae-448d-9056-4cea860bc7fb",
      "evidence": "Venn diagram showing market expansion from Strensiq to ALXN1850",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 49,
      "from": 30,
      "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}